Related Experiment Video
Updated: Jun 3, 2026
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction
Hirokazu Shiheido1, Hideaki Takashima, Nobuhide Doi
1Department of Biosciences and Informatics, Keio University, Yokohama, Japan.
Abstract:
p53 is a tumor suppressor protein that prevents tumorigenesis through cell cycle arrest or apoptosis of cells in response to cellular stress such as DNA damage. Because the oncoprotein MDM2 interacts with p53 and inhibits its activity, MDM2-p53 interaction has been a major target for the development of anticancer drugs. While previous studies have used phage display to identify peptides (such as DI) that inhibit the MDM2-p53 interaction, these peptides were not sufficiently optimized because the size of the phage-displayed random peptide libraries did not cover all of the possible sequences. In this study, we performed selection of MDM2-binding peptides from large random peptide libraries in two stages using mRNA display. We identified an optimal peptide named MIP that inhibited the MDM2-p53 and MDMX-p53 interactions 29- and 13-fold more effectively than DI, respectively. Expression of MIP fused to the thioredoxin scaffold protein in living cells by adenovirus caused stabilization of p53 through its interaction with MDM2, resulting in activation of the p53 pathway. Furthermore, expression of MIP also inhibited tumor cell proliferation in a p53-dependent manner more potently than DI. These results show that two-stage, mRNA-displayed peptide selection is useful for the rapid identification of potent peptides that target oncoproteins.
Insights
Researchers developed a potent peptide, MIP, to inhibit oncoprotein interactions with the tumor suppressor p53. This peptide stabilizes p53, activating its tumor-suppressing pathways and inhibiting cancer cell growth more effectively than previous methods.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- p53 is a crucial tumor suppressor protein that halts cancer progression via cell cycle arrest or apoptosis.
- The oncoprotein MDM2 inhibits p53 activity, making the MDM2-p53 interaction a key target for anticancer drug development.
Purpose of the Study:
- To identify and optimize peptides that inhibit the MDM2-p53 interaction using a novel selection method.
- To evaluate the efficacy of the optimized peptide in stabilizing p53 and inhibiting tumor cell proliferation.
Main Methods:
- Utilized a two-stage mRNA display selection process to identify MDM2-binding peptides from large random peptide libraries.
- Engineered and expressed a thioredoxin-fused MIP peptide in living cells via adenovirus delivery.
- Assessed peptide-mediated p53 stabilization, p53 pathway activation, and tumor cell proliferation inhibition.
Main Results:
- Identified an optimal peptide, MIP, which inhibits MDM2-p53 and MDMX-p53 interactions significantly more effectively than the previously identified peptide DI.
- Adenovirus-mediated expression of MIP led to p53 stabilization and activation of the p53 pathway in cells.
- MIP demonstrated potent, p53-dependent inhibition of tumor cell proliferation, outperforming DI.
Conclusions:
- Two-stage mRNA display is an effective strategy for rapidly identifying potent peptides targeting oncoproteins.
- The novel peptide MIP shows significant potential as an anticancer therapeutic by targeting the MDM2-p53 interaction and restoring p53 tumor suppressor function.
